Can we use tocilizumab in patients with rheumatoid arthritis and high cardiovascular risk? Review article
Article Sidebar
Published:
Jun 30, 2019
Keywords:
tocilizumab, cardiovascular complications, rheumatoid arthritis, biopharmaceutical
Main Article Content
Abstract
Greater rheumatoid arthritis (RA) disease activity has been shown to increase CVD risk and may be related to a variety of pro-inflammatory cytokines and inflammatory markers that may also promote atherosclerosis. Tocilizumab is effective in the treatment of RA. Lipid disorders during treatment do not increase the average atherogenic index or the risk of cardiovascular episodes.
Article Details
How to Cite
Kur-Zalewska, J., & Dąbrowski , R. (2019). Can we use tocilizumab in patients with rheumatoid arthritis and high cardiovascular risk?. Medycyna Faktow (J EBM), 12(2(43), 115-119. https://doi.org/10.24292/01.MF.0219.5
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Goodson N., Marks J., Lunt M., Symmons D.: Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann. Rheum. Dis. 2005; 64: 1595-1601.
2. Lindhardsen J., Ahlehoff O., Gislason G.H. et al.: The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann. Rheum. Dis. 2011; 70: 929-934.
3. Van Helm V.P., Nielen M.M., Nurmohamed M.T. et al.: Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 184-188.
4. Khovidhunkit W., Kim M.S., Memon R.A. et al.: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid. Res. 2004; 45: 1169-1196.
5. Choy E., Sattar N.: Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann. Rheum. Dis. 2009; 68: 460-469.
6. Kaplan M.J.: Cardiovascular disease in rheumatoid arthritis. Curr. Opin. Rheumatol. 2006; 18: 289-297.
7. Agca R., Heslinga S.C., Rollefstad S. et al.: EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis. 2017; 76: 17-28.
8. Bacchiega B.C., Bacchiega A.B., Usnayo M.J. et al.: Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study. J. Am. Heart Assoc. 2017; 6: e005038.
9. Charakterystyka produktu leczniczego: RoActemra.
10. Smolen J.S., Landewé R., Bijlsma J. et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 2017; 0: 1-18. DOI: 10.1136/annrheumdis-2016-210715.
11. Maini R.N., Taylor P.C., Szechinski J. et al.: Double-Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist, Tocilizumab, in European Patients With Rheumatoid Arthritis Who Had an Incomplete Response to Methotrexate. Arthritis Rheum. 2006; 54: 2817-2829.
12. Giles J.T., Sattar N., Gabriel S.E. et al.: Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trial. Arthr. Rheumatol. 2016; 68(10): 4357-4359.
13. Nishimoto N., Miyasaka N., Yamamoto K. et al.: Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis. 2009; 68: 1580-1584. DOI: 10.1136/ard.2008.092866.
14. Jones G., Wallace T., McIntosh M.J. et al.: Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study. J. Rheumatol. 2017; 44: 2. DOI: 10.3899/jrheum.160287.
15. Rao V.U., Pavlov A., Klearman M. et al.: An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy. Arthritis Rheumatol. 2015; 67: 372-380.
16. Schiff M.H., Kremer J.M., Jahreis A. et al.: Integrated safety in tocilizumab clinical trials. Arthritis Res. Ther. 2011; 13(5): R141. DOI: 10.1186/ar3455.
17. Yamamoto K., Goto H., Hirao K. et al.: Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan. J. Rheumatol. 2015; 42: 8.
18. Kim S.C., Solomon D.H., Rogers J.R. et al.: Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis. A Multi-Database Cohort Study. Arthritis Rheum. 2017; 69(6): 1154-1164.
2. Lindhardsen J., Ahlehoff O., Gislason G.H. et al.: The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann. Rheum. Dis. 2011; 70: 929-934.
3. Van Helm V.P., Nielen M.M., Nurmohamed M.T. et al.: Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 2007; 66: 184-188.
4. Khovidhunkit W., Kim M.S., Memon R.A. et al.: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid. Res. 2004; 45: 1169-1196.
5. Choy E., Sattar N.: Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann. Rheum. Dis. 2009; 68: 460-469.
6. Kaplan M.J.: Cardiovascular disease in rheumatoid arthritis. Curr. Opin. Rheumatol. 2006; 18: 289-297.
7. Agca R., Heslinga S.C., Rollefstad S. et al.: EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis. 2017; 76: 17-28.
8. Bacchiega B.C., Bacchiega A.B., Usnayo M.J. et al.: Interleukin 6 Inhibition and Coronary Artery Disease in a High-Risk Population: A Prospective Community-Based Clinical Study. J. Am. Heart Assoc. 2017; 6: e005038.
9. Charakterystyka produktu leczniczego: RoActemra.
10. Smolen J.S., Landewé R., Bijlsma J. et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 2017; 0: 1-18. DOI: 10.1136/annrheumdis-2016-210715.
11. Maini R.N., Taylor P.C., Szechinski J. et al.: Double-Blind Randomized Controlled Clinical Trial of the Interleukin-6 Receptor Antagonist, Tocilizumab, in European Patients With Rheumatoid Arthritis Who Had an Incomplete Response to Methotrexate. Arthritis Rheum. 2006; 54: 2817-2829.
12. Giles J.T., Sattar N., Gabriel S.E. et al.: Comparative cardiovascular safety of tocilizumab vs etanercept in rheumatoid arthritis: results of a randomized, parallel-group, multicenter, noninferiority, phase 4 clinical trial. Arthr. Rheumatol. 2016; 68(10): 4357-4359.
13. Nishimoto N., Miyasaka N., Yamamoto K. et al.: Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann. Rheum. Dis. 2009; 68: 1580-1584. DOI: 10.1136/ard.2008.092866.
14. Jones G., Wallace T., McIntosh M.J. et al.: Five-year Efficacy and Safety of Tocilizumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Methotrexate- and Biologic-naive or Free of Methotrexate for 6 Months: the AMBITION Study. J. Rheumatol. 2017; 44: 2. DOI: 10.3899/jrheum.160287.
15. Rao V.U., Pavlov A., Klearman M. et al.: An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy. Arthritis Rheumatol. 2015; 67: 372-380.
16. Schiff M.H., Kremer J.M., Jahreis A. et al.: Integrated safety in tocilizumab clinical trials. Arthritis Res. Ther. 2011; 13(5): R141. DOI: 10.1186/ar3455.
17. Yamamoto K., Goto H., Hirao K. et al.: Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan. J. Rheumatol. 2015; 42: 8.
18. Kim S.C., Solomon D.H., Rogers J.R. et al.: Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis. A Multi-Database Cohort Study. Arthritis Rheum. 2017; 69(6): 1154-1164.